- Report
- October 2021
- 124 Pages
Asia Pacific
From €1449EUR$1,500USD£1,240GBP
- Report
- October 2021
- 110 Pages
North America
From €1449EUR$1,500USD£1,240GBP
- Report
- October 2021
- 125 Pages
Europe
From €1449EUR$1,500USD£1,240GBP
- Report
- October 2021
- 124 Pages
Middle East, Africa
From €1449EUR$1,500USD£1,240GBP
- Drug Pipelines
- March 2021
Global
From €1932EUR$2,000USD£1,653GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$3,882USD£3,100GBP
- Report
- April 2021
- 375 Pages
Global
From €2415EUR$2,500USD£2,066GBP
- Report
- July 2022
- 274 Pages
Global
From €5621EUR$5,820USD£4,810GBP
- Report
- March 2020
- 118 Pages
Global
From €4346EUR$4,500USD£3,719GBP
The Immune Disorders Drugs market includes drugs used to treat Inflammatory Bowel Disease (IBD). IBD is a chronic condition that causes inflammation of the digestive tract, leading to abdominal pain, diarrhea, and other symptoms. IBD drugs are used to reduce inflammation and improve symptoms. These drugs include corticosteroids, immunomodulators, biologics, and other medications. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunomodulators are used to modify the immune system's response to inflammation. Biologics are used to target specific molecules involved in the inflammatory process.
Some companies in the IBD drug market include AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Merck, Pfizer, and Takeda. Show Less Read more